Pharmacokinetic studies in migraine: what questions should physicians ask?
Migraine is a benign self-limiting condition for which the objective of treatment is to maximize the patient's quality of life by reducing the frequency of attacks and attenuating the pain and suffering of an individual attack as quickly and safely as possible. Evaluating the efficacy of antimigraine treatments, particularly those for the management of the acute attack, is relatively easy because acute symptomatic benefit is the criterion of success. For prophylaxis, therapeutic success generally is measured by relatively simple parameters such as attack frequency. Given that the clinical response to antimigraine therapies relatively is readily assessed by history, the role of more sophisticated investigations such as pharmacokinetic studies may not be immediately clear. This paper aims to provide clinicians with a guide to interpretation of such studies.
Rolan
Paul
P
Department of Neurology, Manchester Royal Infirmary, Oxford Road, Manchester, UK. P.Rolan@Medeval.com
D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism* / Q000517:prevention & control; D010819:Physician's Role; D016896:Treatment Outcome
D000700:Analgesics